Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Location: United States, Pennsylvania, Malvern
Employees: 11-50
Total raised: $260M
Founded date: 2009
Investors 5
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Centennial... | centennial... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 20.09.2018 | Series C | $150M | New Enterp... |
| 28.11.2016 | - | $57M | Sofinnova ... |
| 03.02.2016 | Series B | $5M | - |
| 14.10.2015 | Series B | $37M | - |
| 11.12.2012 | Series A | $11M | - |
Mentions in press and media 17
| Date | Title | Description |
| 21.09.2018 | Term Sheet — Friday, September 21 | ‘WHO CARES’ Happy Friday, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop In a Medium post (with a photo too dramatic for a post on venture capital), Palihapitiya explains that it became “easi... |
| 20.09.2018 | NEA Joins $150M Series C for Galera Therapeutics | Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a ... |
| 20.09.2018 | Galera Therapeutics Raises $150M Series C | Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a ... |
| 20.09.2018 | Galera Therapeutics raises $150M Series C round to fund clinical development | The company plans to use the funding to advance clinical development of its lead drug candidate, GC4419, and to fund a registrational Phase III trial in patients with severe oral mucositis. According to the Oral Cancer Foundation, oral muco... |
| 29.11.2016 | Term Sheet — Tuesday, November 29 | Today in Fallen Unicorns Two shareholders have filed a class action lawsuit against Theranos, accusing the company of fraud and negligence. I believe it’s not terribly common to see private companies involved in class action shareholder law... |
| 28.11.2016 | Galera Therapeutics Expands Series B to $57 Million | MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc., a clinical-stage biotechnology company developing transformational new treatments for cancer patients, announced today it has received $15 million in funding from new investor Sofinn... |
| 28.11.2016 | Galera Therapeutics Receives $15M from Sofinnova Ventures | Galera Therapeutics, Inc., a Malvern, PA-based clinical-stage biotechnology company developing new treatments for cancer patients, received $15m in funding from new backer Sofinnova Ventures. The investment brought the total amount raised i... |
| 28.11.2016 | Galera Therapeutics Expands Series B to $57M | MALVERN, PA, Biotechnology company developing transformational new treatments for cancer patients, has received $15 million in funding from new investor Sofinnova Ventures. >> Click here for more funding data on Galera Therapeutics... |
| 03.02.2016 | Galera Therapeutics Raises $5M; Closes 42M Series B Round | Galera Therapeutics, Inc., a Malvern, PA-based clinical-stage biotech company developing new treatments for cancer patients, received an additional $5m in funding. Enso Ventures made the investment, which brought Series B financing total to... |
| 14.10.2015 | Galera Therapeutics Completes $37M Series B Financing | Galera Therapeutics, Inc., a Malvern, PA-based clinical-stage biotech company developing new treatments for cancer patients, completed a $37m Series B financing. The round was led by Novo Ventures, with participation from existing investors... |
Show more